FNY Managed Accounts’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

FNY Managed Accounts’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-560	Closed	-$6K	–	937
2017 Q3	$6K	Buy	+560	New	+$6.18K	0.01%	503
2015 Q3	–	Sell	-1,900	Closed	-$18.7K	–	653
2015 Q2	$18.7K	Buy	+1,900	New	+$17.3K	0.02%	244

FNY Managed Accounts's SCLN Position: Q4 2017 in Review

FNY Managed Accounts sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 560 shares — an estimated $6K sold.

FNY Managed Accounts first reported a position in SCLN in Q2 2015 and held it in 2 quarters. The position peaked at $18.7K in Q2 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

FNY Managed Accounts reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 560 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $6K.
FNY Managed Accounts first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 2 quarters.
FNY Managed Accounts's Sciclone Pharmaceuticals Inc position peaked at $18.7K in Q2 2015.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.